Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice

N/ATerminatedNCT01748591

Ferring Pharmaceuticals3,324 enrolled

Overview

A Confirmation of Safety, Tolerance and Efficacy of PICOPREP in Clinical Practice.

Study Type

OBSERVATIONAL

Enrollment

3,324

Conditions

Bowel Cleanliness

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients eligible for treatment with PICOPREP® for bowel cleansing prior to endoscopic examination or surgery Exclusion Criteria: * Patients in which prescription of PICOPREP® is contraindicated

Locations (22)

Nemocnice Rudolfa a Stefanie

Benešov, Czechia

Nemocnice Blansko

Blansko, Czechia

Outcomes

Primary Outcomes

The Frequency of Adverse Events

Time frame: 2 days

The Severity of Adverse Events

Time frame: 2 days

Secondary Outcomes

Treatment efficacy measured by assessment of the quality of colon cleaning

Time frame: 2 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.